PET-based compartmental modeling of 124I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer

[1]  K D Wittrup,et al.  Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[2]  A. Scott,et al.  Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Scott,et al.  Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  W. S. Snyder,et al.  Report of the task group on reference man , 1979, Annals of the ICRP.

[5]  P. Bunn,et al.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.

[6]  M. Goris,et al.  Dosimetry model for radioactivity localized to intestinal mucosa. , 2004, Cancer biotherapy & radiopharmaceuticals.

[7]  J. Sakamoto,et al.  Organ-specific expression of the intestinal epithelium-related antigen A33, a cell surface target for antibody-based imaging and treatment in gastrointestinal cancer , 2000, Cancer Chemotherapy and Pharmacology.

[8]  Michael M. Schmidt,et al.  A33 antigen displays persistent surface expression , 2008, Cancer Immunology, Immunotherapy.

[9]  R C Boston,et al.  Conversational SAAM--an interactive program for kinetic analysis of biological systems. , 1981, Computer programs in biomedicine.

[10]  A. Scott,et al.  A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma , 2006, Cancer science.

[11]  J. Chatal,et al.  Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Lloyd J. Old,et al.  Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma , 2005, Clinical Cancer Research.

[13]  A. Scott,et al.  Immuno-PET of human colon xenograft- bearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  J. Humm,et al.  124I-huA33 Antibody Uptake Is Driven by A33 Antigen Concentration in Tissues from Colorectal Cancer Patients Imaged by Immuno-PET , 2011, The Journal of Nuclear Medicine.

[15]  A. Scott,et al.  Rapid and specific targeting of monoclonal antibody A33 to a colon cancer xenograft in nude mice. , 1998, International journal of oncology.

[16]  N. Kemeny,et al.  Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  F. Real,et al.  Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Owens,et al.  Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy. , 1995, British Journal of Cancer.

[19]  O. Boerman,et al.  Cancer Imaging and Therapy with Bispecific Antibody Pretargeting. , 2007, Update on cancer therapeutics.

[20]  C Cobelli,et al.  SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. , 1998, Metabolism: clinical and experimental.

[21]  R. Moritz,et al.  The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[22]  N. Kemeny,et al.  Phase I study of anticolon cancer humanized antibody A33. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  S. Larson,et al.  Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  C Cobelli,et al.  Compartmental models: theory and practice using the SAAM II software system. , 1998, Advances in experimental medicine and biology.

[25]  J. Humm,et al.  124I-huA33 Antibody PET of Colorectal Cancer , 2011, The Journal of Nuclear Medicine.